{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:09:30Z","timestamp":1790104170344,"version":"4.0.1"},"reference-count":61,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pennsylvania Department of Health using Tobacco CURE Funds","award":["141597-216"],"award-info":[{"award-number":["141597-216"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Colorectal cancer is one of the most common malignant diseases in the United States and worldwide, and it remains among the top three causes of cancer-related death. A new understanding of molecular characteristics has changed the profile of colorectal cancer and its treatment. Even controlling for known mutational differences, tumor side of origin has emerged as an independent prognostic factor, and one that impacts response to therapy. Left- and right-sided colon cancers differ in a number of key ways, including histology, mutational profile, carcinogenesis pathways, and microbiomes. Moreover, the frequency of certain molecular features gradually changes from the ascending colon to rectum. These, as well as features yet to be identified, are likely responsible for the ongoing role of tumor sidedness and colorectal subsites in treatment response and prognosis. Along with tumor molecular profiling, blood-based biopsy enables the identification of targetable mutations and predictive biomarkers of treatment response. With the application of known tumor characteristics including sidedness and subsites as well as the utilization of blood-based biopsy, along with the development of biomarkers and targeted therapies, the field of colorectal cancer continues to evolve towards the personalized management of a heterogeneous cancer.<\/jats:p>","DOI":"10.3390\/jpm13071114","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:35:21Z","timestamp":1688949321000},"page":"1114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment"],"prefix":"10.3390","volume":"13","author":[{"given":"Sasha","family":"Waldstein","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA"},{"name":"Vancouver Clinic, Vancouver, WA 98664, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Spengler","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA"},{"name":"Wellspan Medical Oncology & Hematology, Lebanon, PA 17042, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna V.","family":"Pinchuk","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Cancer Control Program, Penn State Cancer Institute, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1457-9047","authenticated-orcid":false,"given":"Nelson S.","family":"Yee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Next-Generation Therapies Program, Penn State Cancer Institute, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ijc.10635","article-title":"Are there two sides to colorectal cancer?","volume":"101","author":"Iacopetta","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5114\/aoms.2016.58596","article-title":"Right- and left-sided colon cancer\u2014Clinical and pathological differences of the disease entity in one organ","volume":"13","author":"Mik","year":"2017","journal-title":"Arch. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"djw322","DOI":"10.1093\/jnci\/djw322","article-title":"Colorectal Cancer Incidence Patterns in the United States, 1974-2013","volume":"109","author":"Siegel","year":"2017","journal-title":"J. Natl Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/DCR.0000000000001062","article-title":"Left-Sided Dominance of Early-Onset Colorectal Cancers: A rationale for screening flexible sigmoidoscopy in the young","volume":"61","author":"Lior","year":"2018","journal-title":"Dis. Colon Rectum"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.clcc.2018.10.002","article-title":"Rising Proportion of Young Individuals with Rectal and Colon Cancer","volume":"18","author":"Kasi","year":"2019","journal-title":"Clin. Color. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.14740\/gr1062w","article-title":"Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature","volume":"11","author":"Baran","year":"2018","journal-title":"Gastroenterol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"86356","DOI":"10.18632\/oncotarget.21169","article-title":"Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers","volume":"8","author":"Salem","year":"2017","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3393\/ac.2018.12.17","article-title":"Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer","volume":"34","author":"Kim","year":"2018","journal-title":"Ann. Coloproctol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1634\/theoncologist.2019-0552","article-title":"Molecular analyses of left- and right-sided tumors in adolescents and young adults with colorectal cancer","volume":"25","author":"Salem","year":"2020","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/gutjnl-2011-300865","article-title":"Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum","volume":"61","author":"Yamaguchi","year":"2012","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1078-0432.CCR-17-2484","article-title":"Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes","volume":"24","author":"Loree","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tarashi, S., Siadat, S.D., Badi, S.A., Zali, M., Biassoni, R., Ponzoni, M., and Moshiri, A. (2019). Gut Bacteria and their Metabolites: Which one is the Defendant for Colorectal Cancer?. Microorganisms, 7.","DOI":"10.3390\/microorganisms7110561"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mohamed, A., Menon, H., Chulkina, M., Yee, N.S., and Pinchuk, I.V. (2021). Drug-Microbiota Interaction in Colon Cancer Therapy: Impact of Antibiotics. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030259"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s10096-017-3026-4","article-title":"Mucosa-associated microbiota signature in colorectal cancer","volume":"36","author":"Gao","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"18321","DOI":"10.1073\/pnas.1406199111","article-title":"Microbiota organization is a distinct feature of proximal colorectal cancers","volume":"111","author":"Dejea","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1172\/JCI124196","article-title":"Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic","volume":"129","author":"Tomkovich","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1136\/gutjnl-2019-318593","article-title":"Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989\u20132012: A matched case-control study","volume":"68","author":"Zhang","year":"2019","journal-title":"Gut"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41416-019-0701-5","article-title":"The association between colorectal cancer and prior antibiotic prescriptions: Case control study","volume":"122","author":"Armstrong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_22","first-page":"djab125","article-title":"Antibiotics Use and Subsequent Risk of Colorectal Cancer: A Swedish Nationwide Population-Based","volume":"114","author":"Lu","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","article-title":"Prognostic Survival Associated with Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-Analysis","volume":"3","author":"Petrelli","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/jco.2016.34.4_suppl.578","article-title":"Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC)","volume":"34","author":"Matos","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/DCR.0000000000000426","article-title":"Difference in time to locoregional recurrence between patients with right-sided and left-sided colon cancers","volume":"58","author":"Park","year":"2015","journal-title":"Dis. Colon Rectum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.clcc.2018.10.005","article-title":"Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis","volume":"18","author":"Li","year":"2019","journal-title":"Clin. Color. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"568417","DOI":"10.3389\/fonc.2020.568417","article-title":"Adjuvant chemotherapy and tumor sidedness in stage II colon cancer: Analysis of the National Cancer data base","volume":"10","author":"Mukkamalla","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4174\/astr.2019.96.6.296","article-title":"Impact of tumor sidedness on survival and recurrence patterns in colon cancer patients","volume":"96","author":"Lee","year":"2019","journal-title":"Ann. Surg. Treat. Res."},{"key":"ref_29","first-page":"3393","article-title":"The prognosis and recurrence pattern of right- and left- sided colon cancer in Stage II, Stage III, and liver metastasis after curative resection","volume":"10","author":"Nakamura","year":"2020","journal-title":"Ann. Coloproctol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"dju427","DOI":"10.1093\/jnci\/dju427","article-title":"Primary tumor location as a prognostic factor in metastatic colorectal cancer","volume":"107","author":"Loupakis","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cam4.1558","article-title":"Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis","volume":"7","author":"Kamran","year":"2018","journal-title":"Cancer Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00535-023-01955-2","article-title":"Prognostic role of detailed colorectal location and tumor molecular features: Analyses of 13,101 colorectal cancer patients including 2994 early-onset cases","volume":"58","author":"Ugai","year":"2023","journal-title":"J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41416-018-0304-6","article-title":"Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer","volume":"119","author":"Loupakis","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Folprecht","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and Predictive Relevance of Primary Tumor Location in Patients with RAS Wild-type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","article-title":"Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first line panitumumab studies","volume":"28","author":"Boeckx","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","article-title":"Final analysis of the randomized PEAK trial: Overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma","volume":"32","author":"Rivera","year":"2017","journal-title":"Int. J. Color. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined with Cetuximab or Bevacizumab on Overall Survival in Patients with KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2017.35.15_suppl.3503","article-title":"Primary (1\u00b0) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (CRC): Analysis of CALGB\/SWOG 80405 (Alliance)","volume":"35","author":"Venook","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamasurg.2017.3466","article-title":"Association of primary tumor site with mortality in patients receiving bevacizumab and cetuximab for metastatic colorectal cancer","volume":"153","author":"Aljehani","year":"2018","journal-title":"JAMA Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ejca.2015.03.015","article-title":"Location of colon cancer (right-sided versus left-sided) as aprognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","volume":"51","author":"Jonker","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1634\/theoncologist.2016-0084","article-title":"Location of Primary Tumor and Benefit from Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer","volume":"21","author":"Moretto","year":"2016","journal-title":"Oncologist"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N. Eng. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/annonc\/mdy140","article-title":"Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO","volume":"29","author":"Cremolini","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E \u2013Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1200\/JCO.2020.38.15_suppl.4001","article-title":"Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)","volume":"38","author":"Kopetz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Hurwitz","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2 \u2013positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open label, phase 2 trial","volume":"17","author":"Trusolino","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"viii714","DOI":"10.1093\/annonc\/mdy424.019","article-title":"Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high\/mismatch repair deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC)","volume":"29","author":"Lenz","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2020.38.4_suppl.11","article-title":"Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high\/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update","volume":"38","author":"Lenz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA4","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high\/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study","volume":"38","author":"Andre","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Vacante, M., Ciuni, R., Basile, F., and Biondi, A. (2020). The liquid biopsy in the management of colorectal cancer: An overview. Biomedicines, 8.","DOI":"10.3390\/biomedicines8090308"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kolencik, D., Shishido, S.N., Pitule, P., Mason, J., Hicks, J., and Kuhn, P. (2020). Liquid biopsy in colorectal carcinoma: Clinical applications and challenges. Cancers, 12.","DOI":"10.3390\/cancers12061376"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kastrisiou, M., Zarkavelis, G., Pentheroudakis, G., and Magklara, A. (2019). Clinical application of next-generation sequencing as a liquid biopsy technique in advanced colorectal cancer: A trick or a treat?. Cancers, 11.","DOI":"10.3390\/cancers11101573"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Nicolazzo, C., Raimondi, C., Gradilone, A., Emiliani, A., Zeuner, A., Francescangeli, F., Belardinilli, F., Seminara, P., Loreni, F., and Magri, V. (2019). Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer. Cancers, 11.","DOI":"10.3390\/cancers11081042"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat. Med."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/7\/1114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:09:36Z","timestamp":1760126976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/7\/1114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jpm13071114"],"URL":"https:\/\/doi.org\/10.3390\/jpm13071114","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]}}}